IL-1α initiates and perpetuates chronic sterile inflammation in the skin. The relatively high concentration of IL-1α on keratinocytes, on open comedomes or on psoriatic skin lesions, makes it a prominent target for therapy. In addition, the strong safety profile of Bermekimab (MABp1), the long half life and its minimal infusion site reactions lends itself to a very efficacious treatment for dermatological indications. XBiotech has a novel asset in Bermekimab (MABp1) with a well understood therapeutic target in IL-1α.